These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 6098475)

  • 1. Time course of the pharmacological response to beta-lactam antibiotics in vitro and in vivo.
    Gerber AU; Feller C; Brugger HP
    Eur J Clin Microbiol; 1984 Dec; 3(6):592-7. PubMed ID: 6098475
    [No Abstract]   [Full Text] [Related]  

  • 2. Synergism of ceftizoxime and tobramycin for Pseudomonas aeruginosa.
    Kim C; Schick DG; Ashley MA; Montgomerie JZ
    J Antimicrob Chemother; 1982 Nov; 10 Suppl C():57-62. PubMed ID: 6296030
    [No Abstract]   [Full Text] [Related]  

  • 3. [Synergistic activity of isepamicin and beta-lactam antibiotics against Pseudomonas aeruginosa in vitro and in vivo].
    Shiritani Y; Yamaji S; Aoki A; Saigusa M; Yokoiyama S; Gato S; Tsuji A
    Jpn J Antibiot; 1988 Nov; 41(11):1591-9. PubMed ID: 3145343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and microbial susceptibility studies of ceftriaxone.
    Baumgartner JD; Glauser MP
    Eur J Clin Microbiol; 1983 Oct; 2(5):501-4. PubMed ID: 6315426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparative effectiveness of gentamycin and other antibiotics in experiment].
    Navashin SM; Fomina IP; Kuznetsova SM
    Antibiotiki; 1969 Aug; 14(8):716-21. PubMed ID: 4314051
    [No Abstract]   [Full Text] [Related]  

  • 6. Routine susceptibility tests with ticarcillin and tobramycin in combination should be more appropriate than with each antibiotic alone in cystic fibrosis Pseudomonas aeruginosa.
    Lapointe JR; Bourget C; Mainville S; Lafleur L; Lagacé J; Montplaisir S
    J Chemother; 1989 Jul; 1(4 Suppl):184-6. PubMed ID: 16312360
    [No Abstract]   [Full Text] [Related]  

  • 7. Antibacterial Properties of Tebipenem Pivoxil Tablet, a New Oral Carbapenem Preparation against a Variety of Pathogenic Bacteria in Vitro and in Vivo.
    Yao Q; Wang J; Cui T; Yang Z; Su M; Zhao P; Yan H; Zhan Y; Yang H
    Molecules; 2016 Jan; 21(1):62. PubMed ID: 26751436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro potency of amikacin and comparators against E. coli, K. pneumoniae and P. aeruginosa respiratory and blood isolates.
    Sutherland CA; Verastegui JE; Nicolau DP
    Ann Clin Microbiol Antimicrob; 2016 Jun; 15(1):39. PubMed ID: 27316973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and laboratory studies with tobramycin.
    Geddes AM; Goodall JA; Speirs CF; Gillett AP; Andrews J; Williams JD
    Chemotherapy; 1974; 20(4):245-56. PubMed ID: 4212996
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical and laboratory investigations on ticarcillin, an anti-pseudomonal antibiotic.
    Wise R; Reeves DS
    Chemotherapy; 1974; 20(1):45-51. PubMed ID: 4210893
    [No Abstract]   [Full Text] [Related]  

  • 11. Differences in suppression of regrowth and resistance despite similar initial bacterial killing for meropenem and piperacillin/tazobactam against Pseudomonas aeruginosa and Escherichia coli.
    Bergen PJ; Bulitta JB; Sime FB; Lipman J; McGregor MJ; Millen N; Paterson DL; Kirkpatrick CMJ; Roberts JA; Landersdorfer CB
    Diagn Microbiol Infect Dis; 2018 May; 91(1):69-76. PubMed ID: 29395712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paradoxical synergism and antagonism between serum and the antibacterial activity of colistin.
    Davis SD; Iannetta A; Wedgwood RJ
    J Infect Dis; 1971 Apr; 123(4):392-8. PubMed ID: 4999904
    [No Abstract]   [Full Text] [Related]  

  • 13. In vitro and in vivo synergy between ceftriaxone and aminoglycosides against Pseudomonas aeruginosa.
    Angehrn P
    Eur J Clin Microbiol; 1983 Oct; 2(5):489-95. PubMed ID: 6315424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Characteristics of current antibiotic therapy].
    Navashin SM; Fomina IP
    Klin Med (Mosk); 1979 Jul; 57(7):10-23. PubMed ID: 113612
    [No Abstract]   [Full Text] [Related]  

  • 15. In vivo significance of the inoculum effect of antibiotics on Escherichia coli.
    Soriano F; Santamaría M; Ponte C; Castilla C; Fernández-Roblas R
    Eur J Clin Microbiol Infect Dis; 1988 Jun; 7(3):410-2. PubMed ID: 3137046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evolution of susceptibility to antibiotics of Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumanii, in a University Hospital Center of Beirut between 2005 and 2009].
    Hamouche E; Sarkis DK
    Pathol Biol (Paris); 2012 Jun; 60(3):e15-20. PubMed ID: 21719212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extended-spectrum β-lactamase-producing Escherichia coli contributes to the survival of cefotaxime-susceptible E. coli under high concentrations of cefotaxime by acquisition of increased AmpC expression.
    Nakayama T; Kawahara R; Kumeda Y; Yamamoto Y
    FEMS Microbiol Lett; 2018 Mar; 365(5):. PubMed ID: 29361027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous simulation of the serum profiles of two antibiotics and analysis of the combined effect against a culture of Pseudomonas aeruginosa.
    Bauernfeind A; Jungwirth R; Petermüller C
    Chemotherapy; 1982; 28(5):334-40. PubMed ID: 6291866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of various antibiotics and the new gentamicin preparation against various pathogenic microbes].
    Jedlicková Z; Výmola F
    Zentralbl Bakteriol Orig; 1968; 208(3):462-6. PubMed ID: 4988546
    [No Abstract]   [Full Text] [Related]  

  • 20. New penicillins in the treatment of urinary tract infection.
    Geedes AM; McGhie D; Hutchison JG; Mahood CB
    Kidney Int Suppl; 1975 Aug; 4():S134-7. PubMed ID: 811918
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.